ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Genentech (RHHBY)'s Cancer-Fighting T-DM1 Leads FDA Class of 2013


12/27/2012 8:13:51 AM

Meet the Bay Area's next blockbuster drug: T-DM1, a breast cancer-fighting treatment developed by Genentech Inc., leads the early Class of 2013 drugs seeking Food and Drug Administration approval. The FDA's decision date is Feb. 26. At least 10 drugs developed by Bay Area companies face FDA approval in the first few months of 2013. That is on top of the record 16 Bay Area drugs approved in 2012. To be sure, some of the wannabe therapies may not pass muster with the agency, which weighs clinical trial data to determine safety and efficacy of a drug. But others, like T-DM1, may win approval before their technical decision dates. For example, the FDA three months early approved the prostate cancer drug Xtandi from San Francisco’s Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. in August. And Onyx Pharmaceuticals Inc. (NASDAQ: ONXX) of South San Francisco won approval July 20 -- a week earlier than expected -- of its multiple myeloma drug Kyprolis. The FDA last month granted T-DM1 "priority review," shaving four months off the agency's review time.

 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES